Teijin Joins COVID-19 Intellectual Property Declaration

Tokyo, Japan, May 8, 2020 --- Teijin Limited announced today that it has joined the OPEN COVID-19 DECLARATION as a founding member to declare that the company will not assert any patent, utility model, design or copyright against any activity purposed with stopping the spread of COVID-19 through diagnosis, prevention, containment or treatment.

The OPEN COVID-19 DECLARATION assures that no rights will be exercised regarding patents, design rights, software program copyrights, or other intellectual property pertaining to development and manufacturing activities aimed at slowing the spread of COVID-19. By eliminating investigations of possible intellectual property right infringement and needs to negotiate licenses, the declaration is designed to facilitate rapid and optimal development and manufacturing activities purposed with stopping the spread of COVID-19.

Industry, government and academia members of the OPEN COVID-19 DECLARATION, through their unified commitment to stopping the spread of COVID-19, acknowledge the need to collaborate, free of constraint by existing practices or conventions, for the swift development and manufacture of products related to COVID-19, including therapeutic agents, vaccines, medical devices and infection-control products.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions”, Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.

Please visit www.teijin.com

Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp